We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

94 hedge funds and large institutions have $237M invested in Phathom Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

15% more funds holding

Funds holding: 82 → 94 (+12)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

10.92% less ownership

Funds ownership: 80.91% → 69.98% (-11%)

32% less capital invested

Capital invested by funds: $349M → $237M (-$112M)

Holders
94
Holders Change
+12
Holders Change %
+14.63%
% of All Funds
1.58%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
22
Increased
31
Reduced
23
Closed
9
Calls
$1.46M
Puts
–
Net Calls
+$1.46M
Net Calls Change
+$178K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$11.2M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$5.87M
3
MVM
Medicxi Ventures Management
Jersey
+$3.94M
4
NM
Newtyn Management
New York
+$2.63M
5
BlackRock
BlackRock
New York
+$2.05M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$9.35M
2
Norges Bank
Norges Bank
Norway
-$8.99M
3
IC
Ikarian Capital
Texas
-$1.07M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$595K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$976K +$555K +53,962 +88%
WSL
27
Western Standard LLC
California
$920K +$1.12M +109,055 New
Morgan Stanley
28
Morgan Stanley
New York
$919K +$249K +24,262 +29%
PVI
29
Pura Vida Investments
New York
$864K – – –
Bank of America
30
Bank of America
North Carolina
$772K +$256K +24,884 +37%
State of Wisconsin Investment Board
31
State of Wisconsin Investment Board
Wisconsin
$741K +$448K +43,540 +98%
PMAM
32
Penn Mutual Asset Management
Pennsylvania
$734K – – –
Walleye Capital
33
Walleye Capital
New York
$701K +$854K +83,031 New
PHP
34
Parkman Healthcare Partners
Connecticut
$583K +$36.8K +3,582 +5%
CIP
35
Chartwell Investment Partners
Pennsylvania
$576K +$387K +37,646 +123%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$544K +$31.6K +3,069 +5%
SEI Investments
37
SEI Investments
Pennsylvania
$538K -$30.2K -2,942 -4%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$525K +$640K +62,258 New
HWAM
39
Hennion & Walsh Asset Management
New Jersey
$477K +$56.1K +5,452 +11%
Marshall Wace
40
Marshall Wace
United Kingdom
$462K +$313K +30,417 +125%
Goldman Sachs
41
Goldman Sachs
New York
$442K +$247K +24,035 +85%
Swiss National Bank
42
Swiss National Bank
Switzerland
$350K +$83.3K +8,100 +24%
Two Sigma Investments
43
Two Sigma Investments
New York
$298K -$50.5K -4,912 -12%
SRA
44
Summit Rock Advisors
New York
$288K – – –
TI
45
Trexquant Investment
Connecticut
$281K +$343K +33,343 New
Two Sigma Advisers
46
Two Sigma Advisers
New York
$278K -$52.4K -5,100 -13%
OAM
47
Occidental Asset Management
California
$250K +$305K +29,672 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$225K +$68.7K +6,681 +33%
Citadel Advisors
49
Citadel Advisors
Florida
$212K +$257K +25,012 New
VM
50
Venator Management
Pennsylvania
$211K +$257K +25,000 New
1
2
3 4 5

PHAT Hedge Fund Activity: Q2 2022 in Review

94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2022, worth a combined $237M — down 32% from $349M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PHAT positions and 9 closed out — a net gain of 13 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $11.2M. The largest seller was Janus Henderson Group, cutting an estimated $9.35M.

  • 94 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2022, up from 82 in Q1 2022.
  • Funds reported $237M of Phathom Pharmaceuticals stock for Q2 2022, down 32% quarter-over-quarter.
  • 22 funds opened new Phathom Pharmaceuticals positions in Q2 2022 and 9 closed out, a net change of +13 holders.
  • The largest Phathom Pharmaceuticals buyer in Q2 2022 was 683 Capital Management, an estimated $11.2M added.
  • The largest Phathom Pharmaceuticals seller in Q2 2022 was Janus Henderson Group, an estimated $9.35M sold.

Based on aggregated 13F filings for Q2 2022.